| Market Capitalization (Millions $) |
5,392 |
| Shares
Outstanding (Millions) |
131 |
| Employees |
739 |
| Revenues (TTM) (Millions $) |
1,105 |
| Net Income (TTM) (Millions $) |
133 |
| Cash Flow (TTM) (Millions $) |
47 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Apellis Pharmaceuticals Inc is a biopharmaceutical company that focuses on discovering, developing, and commercializing novel therapeutics to treat a wide range of diseases. The company is mainly focused on targeting the complement system, which is a part of the immune system responsible for regulating inflammation and immune response.
Apellis Pharmaceuticals has developed a platform called the PEGylation technology, which helps in optimizing the pharmacokinetics and pharmacodynamics of therapeutic compounds. The company's lead product candidate, pegcetacoplan, is being developed for several complement-driven diseases, including paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy (GA), and C3 glomerulopathy (C3G).
The company's goal is to address unmet medical needs by developing innovative therapies that can provide a significant impact on patients' lives. Apellis Pharmaceuticals is dedicated to advancing its product pipeline through rigorous research and clinical trials, and ultimately, to commercialize its investigational therapies for the benefit of patients worldwide.
Company Address: 100 Fifth Avenue Waltham 2451 MA
Company Phone Number: 977-5700 Stock Exchange / Ticker: NASDAQ APLS
|
0.000%
1.7% 
15.39 %